CCI-007 was shown to reduce HOXA9, MEIS1, CMYC and BCL2 mRNA levels within a few hours after treatment in sensitive MLL-r (PER-485, MOLM-13, MV4;11) and CALM-AF10 leukemia (KP-MO-TS) cell lines, while the effects of CCI-007 treatment on expression levels of those genes in resistant leukemia cells were either minimal or absent (Figure 3A and Supplementary Figure S2). This evidence concerns the gene KMT2A and leukemia.